Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
OPRX
OPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OPRX News
OptimizeRx Shares Decline Amid Market Uncertainty
3d ago
Benzinga
OptimizeRx Exceeds Q4 2025 Expectations with Strong Financial Results
4d ago
seekingalpha
OptimizeRx Reports Q4 2025 Earnings Beat with Strong EBITDA Growth
4d ago
seekingalpha
OptimizeRx Set to Announce Q4 Earnings on March 5
5d ago
seekingalpha
Whetstone Capital Fully Exits GitLab Holdings
Feb 26 2026
Fool
Whetstone Capital Fully Exits GitLab Position
Feb 26 2026
NASDAQ.COM
Whetstone Capital Fully Exits monday.com Position
Feb 21 2026
Fool
Whetstone Capital Fully Exits monday.com Position
Feb 21 2026
NASDAQ.COM
OptimizeRx Partners with Experian to Enhance DTC Marketing Effectiveness
Jan 07 2026
Globenewswire
OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%
Dec 17 2025
Globenewswire
OptimizeRx Expands NPI Reach by 37% with Four New Partner Agreements
Dec 17 2025
Newsfilter
Ophirex Secures FDA Agreement for Varespladib Snakebite Treatment Development
Dec 11 2025
Globenewswire
Stephens & Co. Keeps Equal-Weight Rating on OptimizeRx, Reduces Price Target to $17
Nov 17 2025
Benzinga
Top Strong Buy Stocks for November 17: ROKU, AVPT, and Others
Nov 17 2025
NASDAQ.COM
Transcript of OptimizeRx (OPRX) Earnings Call for Q3 2025
Nov 10 2025
NASDAQ.COM
OptimizerRx sets 2026 revenue goal between $118M and $124M, driven by early contract insights and digital pharmaceutical growth.
Nov 07 2025
SeekingAlpha
Show More News
